LMP1/2 CTLs (Group B) for Non-Hodgkin's Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Non-Hodgkin's Lymphoma+4 MoreLMP1/2 CTLs (Group B) - Drug
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether a new experimental therapy, third party LMP specific cytotoxic T lymphocytes (CTLs), can prevent or treat EBV Disorder including either Hodgkin Lymphoma or non-Hodgkin Lymphoma or Lymphoepithelioma or severe chronic active EBV infection syndrome (SCAEBV) or Leiomyosarcoma which has come back or has not gone away after treatment, including the best treatment.

Eligible Conditions
  • Non-Hodgkin's Lymphoma
  • Hodgkin's Lymphoma
  • Leiomyosarcoma
  • Lymphoepithelioma
  • Chronic Active Epstein-Barr Virus Infection Syndrome

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 5 years

5 years
Survival and Immune Function of LMP-specific CTLs
6 weeks
Number of patients with dose limiting toxicity (DLT)
To obtain preliminary information on the safety and response to an extended dosage regimen.

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

LMP1/2 CTLs (Group B)
1 of 2
LMP1/2 CTLs (Group A)
1 of 2

Experimental Treatment

24 Total Participants · 2 Treatment Groups

Primary Treatment: LMP1/2 CTLs (Group B) · No Placebo Group · Phase 1

LMP1/2 CTLs (Group B)
Drug
Experimental Group · 1 Intervention: LMP1/2 CTLs (Group B) · Intervention Types: Drug
LMP1/2 CTLs (Group A)
Drug
Experimental Group · 1 Intervention: LMP1/2 CTLs (Group A) · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

Catherine BollardLead Sponsor
13 Previous Clinical Trials
326 Total Patients Enrolled
Catherine Bollard, MDPrincipal InvestigatorCNMC
6 Previous Clinical Trials
79 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a creatinine level of less than 2x the normal level for your age.
You have a life expectancy > 6 weeks.
You have a score of > 50.
You must have at least 50% donor chimerism in either peripheral blood or bone marrow.
Patients with bilirubin <2x normal, AST <5x normal, and Hgb >8.
You have been off other investigational therapy for at least one month prior to entry in this study.